You are here: Industry Insights > Everest Medicines

News List

Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong PharmaSources
December 03, 2024
Everest Medicines today announced that Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everest’s New Drug Application (NDA).
Everest Medicines, Singapore's EDDC Enter Global Licensing Agreement for COVID Oral Antivirals contractpharma
January 17, 2022
Everest gains exclusive global rights to a series of 3CL protease inhibitors to treat COVID-19.
Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer prnasia
January 11, 2022
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), today announced it will participate in a study pursuant to a clinical trial collaboration between Gilead and MSD...
Everest Medicines Announces Taiwan, China,China FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer prnasia
January 04, 2022
Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Asia...
Providence Therapeutics and Everest Medicines announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program prnewswire
December 21, 2021
Providence Therapeutics and Everest Medicines announced today that their COVID-19 vaccine, PTX-COVID19-B, has been recommended by an independent advisory group to be part of the Solidarity Trial Vaccines ("STV") clinical trial.
Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy prnasia
December 17, 2021
Everest Medicines Limited (HKEX 1952.HK) today reported that Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced that the US Food and Drug Administration (FDA)...
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea prnasia
December 15, 2021
Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products...
Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant prnasia
December 01, 2021
Everest Medicines and Providence Therapeutics ("Providence") jointly announced today that the companies have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant.
Everest Medicines Initiates Submission of New Drug Application in Hong Kong, S.A.R., China for XeravaTM for the Treatment of Complicated Intra-abdominal Infections prnasia
October 13, 2021
Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products...
Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206 prnasia
September 28, 2021
Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asia...